The Corticotropin Releasing Factor Receptor pipeline drugs market research report outlays comprehensive information on the Corticotropin Releasing Factor Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Corticotropin Releasing Factor Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System, Hormonal Disorders, Women’s Health, and Metabolic Disorders which include the indications Central Nervous System, Alzheimer’s Disease, Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endocrine Gland Disorders, Endometriosis, Polycystic Ovarian Syndrome, and Obesity. It also reviews key players involved in Corticotropin Releasing Factor Receptor targeted therapeutics development with respective active and dormant or discontinued products.

The Corticotropin Releasing Factor Receptor pipeline targets constitutes close to 14 molecules. Out of which, approximately 13 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical, and Discovery stages are 1, 3, 6, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Corticotropin Releasing Factor Receptor overview

Corticotropin Releasing Factor Receptor (CRHR) are G-protein-coupled receptors for corticotropin releasing factor (CRF). Two main CRF receptors have been identified, CRF1 and CRF2. CRF has a much higher affinityfor the CRF1 receptor relative to the CRF2 receptor. There are two subtypes of the CRF2 receptor, CRF2A and CRF2B.

For a complete picture of Corticotropin Releasing Factor Receptor’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.